Skip to main content
OpenTrials

Clinical trial condition

Restless Legs Syndrome

Explore clinical trials studying Restless Legs Syndrome. Study availability and eligibility vary by location and protocol.

148 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Restless Legs Syndrome trial results

Completed

Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)

NCT00887289

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Aalen, Germany
  • Boehringer Ingelheim Investigational Site 1 Achim, Germany
  • Boehringer Ingelheim Investigational Site 2 Achim, Germany
  • Boehringer Ingelheim Investigational Site 1 Ahrensburg, Germany
View all 784 locations
View Trial Details
Completed

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

NCT00472199

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • 248.629.4302 Boehringer Ingelheim Investigational Site Innsbruck, Austria
  • 248.629.4304 Boehringer Ingelheim Investigational Site Linz, Austria
  • 248.629.3201 Boehringer Ingelheim Investigational Site Edegem, Belgium
  • 248.629.35801 Boehringer Ingelheim Investigational Site Espoo, Finland
View all 42 locations
View Trial Details
Completed

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

NCT00654498

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • 248.630.04 Boehringer Ingelheim Investigational Site Beijing, China
  • 248.630.05 Boehringer Ingelheim Investigational Site Beijing, China
  • 248.630.06 Boehringer Ingelheim Investigational Site Beijing, China
  • 248.630.07 Boehringer Ingelheim Investigational Site Beijing, China
View all 16 locations
View Trial Details
Completed

Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

NCT00721279

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Absam, Austria
  • Boehringer Ingelheim Investigational Site Absdorf, Austria
  • Boehringer Ingelheim Investigational Site Afritz, Austria
  • Boehringer Ingelheim Investigational Site Alkoven, Austria
View all 127 locations
View Trial Details
Completed

Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

NCT01170091

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site 1 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 2 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 3 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 32 Daegu, South Korea
View all 36 locations
View Trial Details
Completed

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

NCT00152958

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Berlin, Germany
  • Charité Campus Virchow-Klinikum Berlin, Germany
  • emovis GmbH Berlin, Germany
  • Boehringer Ingelheim Investigational Site Chemnitz, Germany
View Trial Details
Completed

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Pivotal Research Centers Peoria, Arizona, United States
  • Mayo Clinic - Scottsdale Scottsdale, Arizona, United States
  • Boehringer Ingelheim Investigational Site Fountain Valley, California, United States
  • HealthQuest Clinical Trials Research San Diego, California, United States
View all 44 locations
View Trial Details
Completed

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

NCT00144209

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Bad Zurzach, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Bern, Switzerland
View Trial Details

Related conditions